LAVA Therapeutics (NASDAQ:LVTX) Trading Down 5.6% – Time to Sell?

LAVA Therapeutics (NASDAQ:LVTX)’s stock price dropped 5.6% during trading on Tuesday . The stock traded as low as $1.63 and last traded at $1.68. Approximately 330,189 shares traded hands during trading, a decline of 39% from the average daily volume of 538,182 shares. The stock had previously closed at $1.78.

Analyst Upgrades and Downgrades

Separately, JMP Securities reissued a “market outperform” rating and set a $6.00 target price on shares of LAVA Therapeutics in a research report on Wednesday, August 21st.

LAVA Therapeutics Stock Down 5.6 %

The company has a current ratio of 6.39, a quick ratio of 6.39 and a debt-to-equity ratio of 0.01. The firm’s 50-day moving average price is $1.71 and its 200 day moving average price is $1.89.

Institutional Investors Weigh In On LAVA Therapeutics

A number of institutional investors have recently added to or reduced their stakes in LVTX. Pathway Financial Advisors LLC grew its position in LAVA Therapeutics by 328.6% in the 2nd quarter. Pathway Financial Advisors LLC now owns 60,000 shares of the company’s stock worth $108,000 after purchasing an additional 46,000 shares in the last quarter. XTX Topco Ltd purchased a new position in LAVA Therapeutics in the second quarter valued at about $55,000. Finally, Virtu Financial LLC purchased a new position in LAVA Therapeutics in the third quarter valued at about $32,000.

LAVA Therapeutics Company Profile

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.